JP2021501566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501566A5 JP2021501566A5 JP2020518692A JP2020518692A JP2021501566A5 JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5 JP 2020518692 A JP2020518692 A JP 2020518692A JP 2020518692 A JP2020518692 A JP 2020518692A JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- amino acid
- antibody
- acid sequence
- transmembrane domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186940A JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Cd138に対する抗体分子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566936P | 2017-10-02 | 2017-10-02 | |
| US62/566,936 | 2017-10-02 | ||
| US201862725880P | 2018-08-31 | 2018-08-31 | |
| US62/725,880 | 2018-08-31 | ||
| PCT/US2018/053989 WO2019070726A1 (en) | 2017-10-02 | 2018-10-02 | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186940A Division JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Cd138に対する抗体分子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501566A JP2021501566A (ja) | 2021-01-21 |
| JP2021501566A5 true JP2021501566A5 (cg-RX-API-DMAC7.html) | 2021-11-11 |
Family
ID=63966111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518692A Pending JP2021501566A (ja) | 2017-10-02 | 2018-10-02 | Cd138に対する抗体分子およびその使用 |
| JP2023186940A Pending JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Cd138に対する抗体分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186940A Pending JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Cd138に対する抗体分子およびその使用 |
Country Status (14)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110691793A (zh) * | 2017-04-26 | 2020-01-14 | 田边三菱制药株式会社 | 黏结蛋白聚糖-1(cd138)结合剂及其用 |
| IL320863A (en) | 2017-10-02 | 2025-07-01 | Visterra Inc | Antibodies to CD138 and their uses |
| BR112021025421A2 (pt) * | 2019-06-17 | 2022-02-01 | Visterra Inc | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| WO2021092044A1 (en) * | 2019-11-05 | 2021-05-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2023275872A1 (en) * | 2021-06-29 | 2023-01-05 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Diagnosis and treatment of pancreatic cancer |
| CN113514645A (zh) * | 2021-07-13 | 2021-10-19 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | CD138抗体联合Mum1抗体在检测浆细胞中的应用 |
| US20230348614A1 (en) | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| CN115120725B (zh) * | 2022-05-30 | 2023-11-07 | 南方医科大学 | Sdc1作为骨质破坏疾病药物治疗靶点的应用 |
| CN115960231B (zh) * | 2022-09-28 | 2026-05-22 | 合肥天港免疫药物有限公司 | 抗cd138的抗体及其应用 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN121021703A (zh) * | 2025-08-26 | 2025-11-28 | 苏州系统医学研究所 | Glyr1特异性抗体、其制备方法及在肿瘤防治中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP1356093A2 (en) | 2000-06-21 | 2003-10-29 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| AU2004224925C1 (en) | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| US20070054332A1 (en) * | 2005-08-10 | 2007-03-08 | Alan Rapraeger | Syndecan 1 ectodomain inhibits cancer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| ES2475201T3 (es) | 2007-12-26 | 2014-07-10 | Biotest Ag | Agentes dirigidos contra CD138 y usos de los mismos |
| US9011864B2 (en) | 2007-12-26 | 2015-04-21 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| US9446146B2 (en) | 2007-12-26 | 2016-09-20 | Biotest Ag | Methods and agents for improving targeting of CD138 expressing tumor cells |
| PL2242772T3 (pl) | 2007-12-26 | 2015-05-29 | Biotest Ag | Immunokonjugaty nakierowane na CD138 i ich zastosowanie |
| CA2761120A1 (en) | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US9249467B2 (en) | 2011-09-16 | 2016-02-02 | Steven Goodison | Bladder cancer detection composition, kit and associated methods |
| US10577543B2 (en) | 2011-10-27 | 2020-03-03 | Raymond Roger Wallage | Efficient oil shale recovery method |
| US10117932B2 (en) | 2011-12-08 | 2018-11-06 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| CA2866612C (en) | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
| GB201216002D0 (en) | 2012-09-07 | 2012-10-24 | Deutsches Rheuma Forschungszentrum Berlin Drfz | Compositions adn methods |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| CN103103197A (zh) | 2013-01-30 | 2013-05-15 | 百奇生物科技(苏州)有限公司 | 抗cd138单克隆抗体可变区序列及其制备方法和应用 |
| RU2611685C2 (ru) | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| IL320863A (en) | 2017-10-02 | 2025-07-01 | Visterra Inc | Antibodies to CD138 and their uses |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| CA3141914A1 (en) | 2019-06-07 | 2020-12-10 | Adimab, Llc | Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use |
| BR112021025421A2 (pt) | 2019-06-17 | 2022-02-01 | Visterra Inc | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos |
| US12590171B2 (en) | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
| US20230348614A1 (en) | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
-
2018
- 2018-10-02 IL IL320863A patent/IL320863A/en unknown
- 2018-10-02 JP JP2020518692A patent/JP2021501566A/ja active Pending
- 2018-10-02 US US16/149,854 patent/US11945868B2/en active Active
- 2018-10-02 MX MX2020003783A patent/MX2020003783A/es unknown
- 2018-10-02 IL IL273572A patent/IL273572B2/en unknown
- 2018-10-02 CN CN201880064634.XA patent/CN111183157A/zh active Pending
- 2018-10-02 SG SG11202002248TA patent/SG11202002248TA/en unknown
- 2018-10-02 AU AU2018345637A patent/AU2018345637A1/en not_active Abandoned
- 2018-10-02 BR BR112020005419-4A patent/BR112020005419A2/pt not_active Application Discontinuation
- 2018-10-02 MY MYPI2020001188A patent/MY205689A/en unknown
- 2018-10-02 EP EP18793101.9A patent/EP3692069A1/en active Pending
- 2018-10-02 CA CA3074032A patent/CA3074032A1/en active Pending
- 2018-10-02 WO PCT/US2018/053989 patent/WO2019070726A1/en not_active Ceased
- 2018-10-02 CN CN202411128002.9A patent/CN119192374A/zh active Pending
- 2018-10-02 KR KR1020207012740A patent/KR20200058540A/ko not_active Ceased
-
2020
- 2020-03-26 PH PH12020550141A patent/PH12020550141A1/en unknown
-
2023
- 2023-10-31 JP JP2023186940A patent/JP2024001294A/ja active Pending
-
2024
- 2024-02-20 US US18/581,992 patent/US20240301065A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7179464B2 (ja) | 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用 | |
| AU2010292342C1 (en) | High affinity human antibodies to human protease-activated receptor-2 | |
| US11945868B2 (en) | Antibody molecules to CD138 and uses thereof | |
| JP2020115876A (ja) | Pd−l1に対するヒト抗体 | |
| JP2023516936A (ja) | Pvrig結合タンパク質及びその医薬用途 | |
| CN106068275A (zh) | 抗pd‑1的人抗体 | |
| JP7604401B2 (ja) | 抗体および使用方法 | |
| KR20230058074A (ko) | Ilt2에 대한 항체 및 이의 용도 | |
| WO2020198370A2 (en) | Therapeutic cd47 antibodies | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| US20250051473A1 (en) | Anti-cd38 binding molecules and uses thereof | |
| JP2026021532A (ja) | Btla抗体 | |
| CA3207703A1 (en) | Anti-s100a4 humanized antibodies, uses and methods | |
| JP2024097985A (ja) | 抗gitr抗体およびその使用 | |
| AU2018361819A1 (en) | Antibodies and methods of use | |
| EP3898694A1 (en) | Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof | |
| KR20230087552A (ko) | Cd45를 다량체화하는 결합 분자 | |
| CN114641500A (zh) | 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法 | |
| CN118679185A (zh) | 抗cd38结合分子及其用途 | |
| HK40114352A (en) | Antibody against btla and uses thereof | |
| CA3250219A1 (en) | ANTIBODIES AGAINST BTLA AND THEIR USES | |
| HK40074321A (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies | |
| EA050239B1 (ru) | Мультиспецифические антитела, связывающиеся с bcma | |
| EA048356B1 (ru) | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 |